Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of PF-06648671 in Healthy Adults and Elderly
NCT02440100Phase 1Completed
- Sponsor
- Pfizer
- Start
- May 2015
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-06648671 in Alzheimer's disease (AD) (9 cohorts), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration at Day 14, Area Under the Curve from Time Zero to 24 Hours and 4 more. Started May 2015; status: completed.
02
Drugs
PF-06648671
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02440100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02440100.